Effect of Fish Oil on Plasma Triglycerides in Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this small, short pilot study is to determine the feasibility (e.g., recruitment, dose acceptance, retention) of a future longer trial comparing the effects of two types of omega-3 fats from fish oil on plasma triglycerides. The two types of fish oil are composed of (1) omega-3 fatty acids in triglyceride form; and (2) as esterified free fatty acids (i.e. ethyl esters). Although these two types of fish oil supplements are available to the public, it remains unclear whether they are equally effective in lowering plasma triglycerides.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels

NCT00441480

Dyslipidemia

COMPLETED PHASE4

Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides

NCT02625870

Hypertriglyceridemia

UNKNOWN PHASE3

Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

NCT01488747

Healthy Adults

COMPLETED NA

Effect of n-3 Fatty Acid Supplementation in Hyperlipidemic Patients Taking Statins

NCT03961763

Cardiovascular Diseases Hyperlipidemias Dyslipidemias

COMPLETED NA

Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil

NCT01313988

Healthy Mildly Elevated Cholesterol Levels

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a double-blinded, parallel design, placebo controlled trial with three active treatment arms to compare the triglyceride (TG) lowering effects of the same dose of EPA and DHA provided in three formulations of supplements that differ in the proportion of omega-3 FA present as ethyl esters vs. triglycerides. The active therapy for each of the three fish oil supplementation arms is 4 g/day of combined EPA and DHA provided as: a) 90% TG formulation, b) 60% TG formulation, or c) ethyl esters (esterified fatty acids)(i.e., 0% TG). The placebo was a soy oil supplement with an identical total fat content. The primary outcome is the 12-week change in TG concentrations in the active groups vs. placebo. Secondary outcomes include LDL particle distribution, defined as either subclasses LDL1, LDL2, LDL3 and LDL4, and LDL subclass phenotype patterns A, B, or A/B.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertriglyceridemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fish oil (90% triglycerides)

Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.

Group Type EXPERIMENTAL